Ireland - English - HPRA (Health Products Regulatory Authority)

primecrown 2010 limited - cholecalciferol; calcium carbonate - chewable tablet - 500/400iu milligram(s) - calcium, combinations with vitamin d and/or other drugs

Ireland - English - HPRA (Health Products Regulatory Authority)

ltt pharma limited - cholecalciferol; calcium carbonate - chewable tablet - 500 mg/400 international unit(s) - calcium, combinations with vitamin d and/or other drugs

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - cholecalciferol; calcium carbonate - chewable tablet - 500 mg/400 international unit(s) - calcium, combinations with vitamin d and/or other drugs

European Union - English - EMA (European Medicines Agency)

bayer ag - radium (223ra) dichloride - prostatic neoplasms - therapeutic radiopharmaceuticals - xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

servier malaysia sdn bhd - perindopril salified with tert-butylamin -

Israel - English - Ministry of Health

bayer israel ltd - radium-223 dichloride - solution for injection - radium-223 dichloride 1100 kbq/ml at reference date - radium (223 ra) dichloride - xofigo monotherapy or in combination with luteinising hormone releasing hormone (lhrh) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for advanced pc (other than lhrh analogues), or ineligible for any available systemic mcrpc treatment.

Israel - English - Ministry of Health

bayer israel ltd - radium-223 dichloride - solution for injection - radium-223 dichloride 1100 kbq/ml at reference date - radium (223 ra) dichloride - xofigo monotherapy or in combination with luteinising hormone releasing hormone (lhrh) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for advanced pc (other than lhrh analogues), or ineligible for any available systemic mcrpc treatment.

Ireland - English - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - sodium bicarbonate; calcium carbonate; sodium alginate - oral suspension - 500 mg+267 mg+160 milligram(s) - antacids, other combinations; other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)

Israel - English - Ministry of Health

novartis israel ltd - vinorelbine as tartrate - concentrate for solution for infusion - vinorelbine as tartrate 10 mg/ml - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer. hormone- refractory prostate cancer, especially in combination with low dose oral corticoid therapy or estramustin.

Israel - English - Ministry of Health

trima trading (1961), israel - vinorelbine as tartrate - concentrate for solution for infusion - vinorelbine as tartrate 10 mg/ml - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.hormone - refractory prostate cancer, especially in combination with low dose oral corticoid therapy or estramustin.